Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14358586 | 0.77 | MEN1 (0.36) | MEN1KMT2AL3MBTL1KDM4C | |
| SCHEMBL2830795 | 0.74 | MEN1 (0.35) | MEN1KMT2AKDM4C | |
| SCHEMBL8871983 | 0.74 | MEN1 (0.35) | MEN1KMT2AKDM4C | |
| SCHEMBL115434 | 0.73 | MEN1 (0.47) | MEN1KMT2AL3MBTL1KDM4C | |
| SCHEMBL21436952 | 0.73 | MEN1 (0.47) | MEN1KMT2AL3MBTL1KDM4C | |
| SCHEMBL2627761 | 0.73 | — | — | |
| SCHEMBL374245 | 0.73 | MEN1 (0.38) | MEN1KMT2AL3MBTL1KDM4C | |
| SCHEMBL29838273 | 0.71 | MEN1 (0.37) | MEN1KMT2AL3MBTL1KDM4C | |
| SCHEMBL29242671 | 0.71 | MEN1 (0.35) | MEN1KMT2AKDM4C | |
| SCHEMBL14358168 | 0.70 | MEN1 (0.33) | MEN1KMT2AL3MBTL1KDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240417408-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12C MUTANT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2024-12-19 | — | — | US | disclosed |
| EP-4347606-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12C MUTANT | Merck Sharp & Dohme LLC (US) | 2024-04-10 | — | — | EP | disclosed |
| WO-2022251576-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12C MUTANT | MERCK SHARP & DOHME CORP. (US) | 2022-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240417408-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12C MUTANT | KRAS, NRAS, HRAS | MEN1 296/4885KMT2A 1474/4885L3MBTL1 4391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.